Last update 24 Dec 2024
Dexrazoxane Hydrochloride
Last update 24 Dec 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms dexrazoxane, Topotect, Totect + [13] |
Target |
Mechanism Top II inhibitors(Topoisomerase II inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (26 May 1995), |
RegulationAccelerated Approval (US), Orphan Drug (AU), Orphan Drug (US) |
Login to view timeline
Structure
Molecular FormulaC11H17ClN4O4 |
InChIKeyBIFMNMPSIYHKDN-FJXQXJEOSA-N |
CAS Registry149003-01-0 |
Related
51
Clinical Trials associated with Dexrazoxane HydrochlorideProspective Treatment of Types I, II and III Pleuropulmonary Blastoma (PPB)
ANTICIPATE: Prevention of ANThracycline-Induced Cardiac Dysfunction by Dexrazoxane In PATients With diffusE Large B-cell Lymphoma: a Phase III National Multicenter Prospective Randomized Open-label Trial
A Phase II, Single Arm, Open Label, Study on the Safety, Efficacy, Pharmacokinetics & Pharmacodynamics of Quizartinib + Chemotherapy and as Single-agent After High Dose Therapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients
100 Clinical Results associated with Dexrazoxane Hydrochloride
Login to view more data
100 Translational Medicine associated with Dexrazoxane Hydrochloride
Login to view more data
100 Patents (Medical) associated with Dexrazoxane Hydrochloride
Login to view more data
850
Literatures (Medical) associated with Dexrazoxane Hydrochloride01 Feb 2025CARDIOLOGY CLINICS
Cardiotoxicity of Anthracyclines
Review
Author: Hoeger, Christopher W. ; Ariza, Abul ; Asnani, Aarti ; Balough, Elizabeth ; Hoeger, Christopher W
Anthracycline chemotherapy is associated with cardiotoxicity, predominantly manifesting as left ventricular systolic dysfunction within the first year of treatment. Early detection is possible through biomarkers and cardiovascular imaging before clinical symptoms develop. Comprehensive cardiovascular risk assessment is essential for all patients prior to anthracycline therapy to stratify their risk of cardiotoxicity. Preventive measures, including cardiovascular risk optimization, as well as anthracycline dose adjustments, the use of liposomal anthracyclines, and dexrazoxane in high-risk patients, are crucial to mitigate the risk of cardiotoxicity. Long-term follow-up and cardiovascular risk optimization are critical for cancer survivors to optimize cardiovascular outcomes.
01 Jan 2025Annals of Hepatology
Lipocalin-2 silencing alleviates sepsis-induced liver injury through inhibition of ferroptosis
Article
Author: Li, Zhenghong ; Ye, Hongwei ; Zhang, Yuming ; Gao, Qin ; Yun, Qi ; Du, Ruoli ; Li, Yuping ; Li, Lu
INTRODUCTION AND OBJECTIVES:
Liver plays a key role in sepsis, a systemic inflammatory response syndrome caused by infection. Ferroptosis is involved in sepsis-induced liver injury. We aimed to assess the changes in ferroptosis in cecal ligation and puncture (CLP)-induced septic mice, and determine the role of lipocalin-2 (LCN2) in liver ferroptosis.
MATERIALS AND METHODS:
CLP was used to induce sepsis in mice. The morphological changes in liver tissues and mitochondrial structure were observed using hematoxylin and eosin staining and transmission electron microscopy. The levels of serum alanine transaminase, aspartate aminotransferase, superoxide dismutase, and malondialdehyde were detected using the corresponding kits. The changes of reactive oxygen species level in liver tissues were detected using dihydroethidium as a fluorescence probe. LCN2, cysteine-glutamate reverse transport system, and dihydroorotate dehydrogenase protein levels in the liver were detected by western blotting. The ferroptosis inhibitor ferrostatin-1 (Fer-1), iron chelator dexrazoxane (DXZ), iron-dextran, and LCN2 knockdown studies were performed to determine role of ferroptosis and LCN2 in liver injury during sepsis.
RESULTS:
Ferroptosis levels increased in the liver tissues of CLP-induced septic mice. Both Fer-1 and DXZ suppressed ferroptosis and attenuated liver injury following sepsis challenge, whereas iron-dextran increased ferroptosis and liver injury in mice with sepsis. LCN2 knockdown suppressed ferroptosis and reduced oxidative stress in the liver.
CONCLUSIONS:
Ferroptosis inhibition attenuates septic liver injury. LCN2 knockdown alleviates sepsis-induced liver injury by inhibiting ferroptosis and reducing oxidative stress.
01 Dec 2024CELL BIOCHEMISTRY AND BIOPHYSICS
Cardioprotective effect of Robinin ameliorates Endoplasmic Reticulum Stress and Apoptosis in H9c2 cells
Article
Author: Abhirami, N ; Ayyappan, Janeesh Plakkal
Robinin is one of the glycosyloxyflavones that has been less explored for its therapeutic application, especially in the field of CVD. Herein, we explored the cardioprotective efficacy of Robinin by using H2O2 and Doxorubicin (DOX) - treated H9c2 cells as an in vitro model. H2O2 and DOX treatment resulted in severe cellular damage to the cardiomyocytes, which was followed by apoptosis. Apoptosis and nuclear morphology were analysed through Hoechst 33342 and AO/EB staining. qPCR was employed to detect the expression of apoptosis as well as ERS-related markers. Reactive oxygen species (ROS) generation was observed using DCFH-DA staining and FACS analysis. Signaling pathways involved were analysed using Western blot. Robinin pre-treatment considerably decreased the apoptotic rate by boosting the endogenous anti-oxidative activity and lowering the activity of Malonaldehyde and Lactate dehydrogenase enzyme. Robinin also inhibited the generation of ROS. Robinin reduced the expression of ERS-associated genes and proteins, thereby decreasing apoptosis-related proteins. Upon comparing the cardioprotective effect of Robinin with a known cardioprotective agent Dexrazoxane (DEX) it was revealed that DEX has more cardioprotective effect against DOX than H2O2-induced stress, while Robinin showed a significant protective effect against both H2O2 and DOX induced stress.
3
News (Medical) associated with Dexrazoxane Hydrochloride11 Aug 2023
AcquisitionLicense out/in
10 Aug 2023
AcquisitionRadiation Therapy
09 Feb 2019
Accelerated ApprovalOrphan DrugFast TrackBreakthrough TherapyDrug Approval
100 Deals associated with Dexrazoxane Hydrochloride
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D07807 | Dexrazoxane Hydrochloride |
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Extravasation of Diagnostic and Therapeutic Materials | EU | 27 Jul 2006 | |
| Extravasation of Diagnostic and Therapeutic Materials | IS | 27 Jul 2006 | |
| Extravasation of Diagnostic and Therapeutic Materials | LI | 27 Jul 2006 | |
| Extravasation of Diagnostic and Therapeutic Materials | NO | 27 Jul 2006 | |
| Cytoprotective Agent | CN | 29 May 2006 | |
| Cardiomyopathies | US | 26 May 1995 | |
| Metastatic breast cancer | US | 26 May 1995 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Hemorrhage | Phase 3 | DK | 01 Apr 2002 | |
| Hemorrhage | Phase 3 | DE | 01 Apr 2002 | |
| Hemorrhage | Phase 3 | IT | 01 Apr 2002 | |
| Hemorrhage | Phase 3 | NL | 01 Apr 2002 | |
| Hemorrhage | Phase 3 | PL | 01 Apr 2002 | |
| Bronchitis | Phase 3 | DK | 01 Jun 2001 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Not Applicable | - | qotuhmcnyn(ihcodjqthw) = cansknmacr vnlcdflsey (qnvnbnigvx ) View more | - | 07 Dec 2024 | |||
Non-initiators of Dexrazoxane | qotuhmcnyn(ihcodjqthw) = yfiajzincx vnlcdflsey (qnvnbnigvx ) View more | ||||||
Not Applicable | 142 | Anthracycline + Dexrazoxane | bmzraddyui(qsozacwwta) = afzrplngvz wbvjbpjkdf (rjrvynteyu ) | Positive | 31 May 2023 | ||
Anthracycline only | bmzraddyui(qsozacwwta) = gtiscnixki wbvjbpjkdf (rjrvynteyu ) View more | ||||||
Not Applicable | - | 195 | nezxvpxlos(ypyuoaoqbu) = xzbfagvcdr dkwzpwieyz (fuwnpmjnis ) | - | 20 Jan 2023 | ||
Doxorubicin with Dexrazoxane | - | ||||||
Not Applicable | 263 | fpniniarll(xllgbllcif) = cqtgqeinmd qbdzdbhlnc (ecctjsibux ) View more | - | 03 Dec 2022 | |||
fpniniarll(xllgbllcif) = rwdvrzwlmk qbdzdbhlnc (ecctjsibux ) View more | |||||||
Not Applicable | - | 1,308 | Doxorubicin with dexrazoxane | hghplexnge(lyrxmnsjhx): HR = 1.07 (95% CI, 0.78 - 1.47) View more | - | 15 Feb 2022 | |
Doxorubicin without dexrazoxane | |||||||
Phase 3 | 236 | Therapeutic Conventional Surgery (Very Low-risk Group) | ttbpxomrne(rqmesvqjcc) = trhmmzuwok uyvkeqvfdo (suyjcjhucw, smciaijnbz - aqunigpeln) View more | - | 28 Dec 2021 | ||
(Low-risk Group (Regimen T)) | ttbpxomrne(rqmesvqjcc) = tbszuzsanx uyvkeqvfdo (suyjcjhucw, xarteocbug - kpmmfefstn) View more | ||||||
Not Applicable | 2,375 | nhxxmeozqt(ovsbvunflu): OR = 1.15 (95% CI, 0.57 - 2.31), P-Value = 0.7 View more | - | 29 Jun 2021 | |||
No drug or placebo | |||||||
Not Applicable | 173 | zkdtuqxtmh(armyfvykoz) = fyvdlajchn tpjgmehkre (urkylhxjoe, 6.0 - 18.0) View more | Positive | 25 May 2020 | |||
zkdtuqxtmh(armyfvykoz) = dzpsdunbhl tpjgmehkre (urkylhxjoe, 6.0 - 28.2) View more | |||||||
Phase 2 | 46 | (Arm A: VACdxr With ImmTher) | kvcoppggjp(hfxxxmxebo) = tgczywpbgj upmbbqlnfg (dgpnmaapix, pevfmdahjb - mujbgezglt) View more | - | 29 Jan 2020 | ||
(Arm B: VACdxr) | kvcoppggjp(hfxxxmxebo) = zjtgncnhmq upmbbqlnfg (dgpnmaapix, susuobjffc - unanvstnml) View more | ||||||
Phase 1 | 1 | pptgkayzkf(jzomcgitez) = bmezuqagzi gacnemkbrw (oceuvuqfoq, nmeyxpfvst - qrmwkxjnfo) View more | - | 19 Feb 2019 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free